US5733939A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Fluorocarbons as anti-inflammatory agents
Assignee: Research Foundation of the State University of New York
•
Filing: 1995-11-22
•
Granted: 1998-03-31
•
Expires: 2015-11-22
Abstract
Abstract A method for reducing the inflammatory response in tissues of a patient, by contacting the tissue with an effective, inflammation-reducing amount of a liquid or gaseous fluorocarbon.
Inventors
- 👤 Bradley Phillip Fuhrman
- 👤 Stephen F. Flaim
- 👤 Lynn Joanne Hernan
- 👤 Frances Darey Nesti
- 👤 Michele Cecile Papo
- 👤 David Marc Steinhorn
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 14:51
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/02; A61K33/00; A61P; A61P1/00; A61P11/00; A61P15/00; A61P15/02; A61P17/00; A61P29/00; A61K9/00; A61K9/0012; A61K9/007; A61K9/0073
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
55 words
A method for reducing inflammation associated with a mucosal, local or systemic inflammatory condition in a patient, comprising the step of administering to said patient an effective inflammation-reducing amount of a liquid or gaseous fluorocarbon, said administration comprising a delivery mode selected from-the group consisting of intravenous, intramuscular, intratracheal, intraarterial, subcutaneous, oral, rectal and topical.
Claim 2
Independent Claim
55 words
A method for reducing inflammation associated with a mucosal, local or systemic inflammatory condition in a patient, comprising the step of administering to said patient an effective inflammation-reducing amount of a liquid or gaseous fluorocarbon, said administration comprising a delivery mode selected from-the group consisting of intravenous, intramuscular, intratracheal, intraarterial, subcutaneous, oral, rectal and topical.
Claim 3
Dependent Claim
15 words
The method of claim 1 wherein said fluorocarbon is in the form of an emulsion.
Claim 4
Dependent Claim
12 words
The method of claim 2 wherein said emulsion is a reverse emulsion.
Claim 5
Dependent Claim
27 words
The method of claim 1 wherein said fluorocarbon is administered in a form selected from the group consisting of aerosols, mists, air-borne suspensions, vapors and combinations thereof.
Claim 6
Dependent Claim
11 words
The method of claim 1, wherein said fluorocarbon is administered systemically.
Claim 7
Dependent Claim
16 words
The method of claim 5, wherein said fluorocarbon is administered in the form of an emulsion.
Claim 8
Dependent Claim
16 words
The method of claim 5, wherein said systemic administration comprises introducing said fluorocarbon to the lungs.
Claim 9
Dependent Claim
15 words
The method of claim 7, wherein said fluorocarbon is in the form of a gas.
Claim 10
Dependent Claim
11 words
The method of claim 7, wherein said fluorocarbon is a liquid.
Claim 11
Dependent Claim
15 words
The method of claim 9, wherein said fluorocarbon is in the form of an aerosol.
Claim 12
Dependent Claim
40 words
The method of claim 1 wherein said inflammatory condition is a result of the patient suffering from a disorder selected from the group consisting of sepsis, peritonitis, colitis, erythematosus, vasculitis, diverticulitis, collagen vascular disease endometriosis, allergic reactions and autoimmune disorders.
Claim 13
Dependent Claim
21 words
The method of claim 1 further comprising the step of administering a breathing gas simultaneously with said liquid or gaseous fluorocarbon.
Claim 14
Dependent Claim
20 words
The method of claim 12 wherein said liquid or gaseous fluorocarbon is administered in the form of a saturated vapor.
Claim 15
Dependent Claim
15 words
The method of claim 1 wherein said fluorocarbon is delivered directly into the peritoneal cavity.
Claim 16
Independent Claim
39 words
A method for reducing inflammation associated with a mucosal, local or systemic inflammatory condition in a patient, said method comprising the step of pulmonarily administering an inflammation-reducing amount of at least one fluorocarbon in conjunction with a breathing gas.
Claim 17
Independent Claim
39 words
A method for reducing inflammation associated with a mucosal, local or systemic inflammatory condition in a patient, said method comprising the step of pulmonarily administering an inflammation-reducing amount of at least one fluorocarbon in conjunction with a breathing gas.
Claim 18
Dependent Claim
20 words
The method of claim 15 wherein said fluorocarbon is selected from the group consisting of liquid fluorocarbons and gaseous fluorocarbons.
Claim 19
Dependent Claim
27 words
The method of claim 15 wherein said fluorocarbon is administered in a form selected from the group consisting of aerosols, mists, air-borne suspensions, vapors and combinations thereof.
Claim 20
Dependent Claim
41 words
The method of claim 15 wherein said systemic inflammatory condition is a result of the patient suffering from a disorder selected from the group consisting of sepsis, peritonitis, colitis, erythematosus, vasculitis, diverticulitis, collagen vascular disease, endometriosis, allergic reactions and autoimmune disorders.
Claim 21
Independent Claim
45 words
A method for reducing inflammation associated with a mucosal, local or systemic inflammatory condition in a patient comprising: administering an inflammation-reducing effective amount of at least one liquid fluorocarbon into a lung of said patient; and subsequently introducing an oxygen-containing breathing gas into said lung.
Claim 22
Independent Claim
45 words
A method for reducing inflammation associated with a mucosal, local or systemic inflammatory condition in a patient comprising: administering an inflammation-reducing effective amount of at least one liquid fluorocarbon into a lung of said patient; and subsequently introducing an oxygen-containing breathing gas into said lung.
Claim 23
Dependent Claim
28 words
The method of claim 19 wherein said liquid fluorocarbon is administered in a form selected from the group consisting of aerosols, mists, air-borne suspensions, vapors and combinations thereof.
Claim 24
Dependent Claim
18 words
The method of claim 19 wherein said liquid fluorocarbon is administered in the form of a saturated vapor.
Claim 25
Dependent Claim
41 words
The method of claim 19 wherein said systemic inflammatory condition is a result of the patient suffering from a disorder selected from the group consisting of sepsis, peritonitis, colitis, erythematosus, vasculitis, diverticulitis, collagen vascular disease, endometriosis, allergic reactions and autoimmune disorders.
References Cited (Backward Citations)
US4044121A
Cited
US4680173A
Cited
US4490351A
Cited
US4543202A
Cited
US5192528A
Cited
US4865836A
Cited
US4927623A
Cited
US4987154A
Cited
WO1989000848A1
Cited
US5284645A
Cited
US4897262A
Cited
US5028428A
Cited
US5225183A
Cited
CA2066046A1
Cited
US5213570A
Cited
WO1992019300A1
Cited
US5290540A
Cited
US5437272A
Cited
US5490498A
Cited
US5470885A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-03-30 | 2001-09-29 | 2002-03-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-03-30 | 2005-09-29 | 2006-03-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-03-30 | 2009-09-29 | 2010-03-31 | $7700.00 | Window Closed / Lapsed |